SCHEMBL10186211

SCHEMBL10186211

CCOc1ccc2cc(C(=O)NCCNC(=O)c3ccc(O[C@H]4CC[C@@H](C(=O)O)CC4)cc3F)ccc2c1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.43
DGAT1 O75907 9/20 0.41
ABL1 P00519 1/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
ACSL1 P33121 2/20 0.40
MAPT P10636 2/20 0.39
SOAT1 P35610 1/20 0.39
KDM4E B2RXH2 1/20 0.39
USP2 O75604 1/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ACHE P22303 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10184390 0.93 NPC1 (0.48) HRH3DGAT1NPC1RAB9AMAPT
SCHEMBL10185426 0.92 ACHE (0.46) HRH3DGAT1NPC1RAB9ASOAT1
SCHEMBL10186479 0.90 ACHE (0.45) HRH3DGAT1NPC1RAB9ASOAT1
SCHEMBL10184537 0.90 DGAT1 (0.46) HRH3DGAT1RAB9AACSL1SOAT1
SCHEMBL10185010 0.90 DGAT1 (0.46) HRH3DGAT1SOAT1
SCHEMBL664102 0.90 DGAT1 (0.46) HRH3DGAT1RAB9AACSL1SOAT1
SCHEMBL664101 0.90 DGAT1 (0.46) HRH3DGAT1RAB9AACSL1SOAT1
SCHEMBL10184363 0.89 HRH3 (0.43) HRH3DGAT1NPC1RAB9ASOAT1
SCHEMBL10184440 0.89 NPC1 (0.49) HRH3DGAT1ABL1NPC1RAB9A
SCHEMBL10185015 0.88 HRH3 (0.42) HRH3DGAT1RAB9AACSL1SOAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND ASTELLAS PHARMA INC. (JP) 2012-02-23 US disclosed
WO-2010122968-A1 DIACYLETHYLENEDIAMINE COMPOUND アステラス製薬株式会社 (JP) 2010-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046292-A1 DIACYLETHYLENEDIAMINE COMPOUND DGAT1, DGAT2, DIMT1 HRH3 2422/4885DGAT1 1/4885ABL1 4254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.